Condition deep-dive · 7 min read

BPH protocol — what supplements actually move IPSS in benign prostatic hyperplasia

Updated 2026-05-15 · Reviewed by SupplementScore editors · No sponsorships

Benign prostatic hyperplasia (BPH) is the dominant cause of lower urinary tract symptoms (LUTS) in men over 50: weak stream, hesitancy, nocturia, urgency, and incomplete emptying. The supplement evidence has a curve to it — saw palmetto's enthusiasm peaked around 2000, the STEP and CAMUS trials dampened the field in the 2010s, and a more nuanced 2020s picture has emerged in which standardised extracts at adequate doses show modest IPSS reductions in mild-to-moderate symptoms. None of these supplements compete with alpha blockers or 5-alpha reductase inhibitors for moderate-to-severe BPH; they fill a niche in mild symptoms or as adjuncts.

Rule out red flags first. Acute urinary retention, gross haematuria, palpable bladder, persistently elevated post-void residual, recurrent UTI, or rising PSA need urology workup — not supplements. Supplements can also mask the prostate-cancer warning of LUTS without addressing it. Men over 50 with new urinary symptoms should have a baseline DRE and PSA and ideally a flow study and post-void residual before starting supplements as monotherapy.

What actually has trial evidence

Tier 2 evidence · Mixed but moderately positive at adequate dose

Saw palmetto (Serenoa repens) — hexane-extracted, standardised

320 mg/day of hexane-extracted Serenoa repens (Permixon-type), divided 160 mg b.i.d.

The CAMUS trial (2011) found no benefit at up to triple-dose lipid extract, dampening enthusiasm. However, hexane-extracted Permixon-type standardised products at 320 mg/day have separate meta-analyses (Vela-Navarrete 2018) showing IPSS reductions comparable to tamsulosin in mild-to-moderate symptoms. The form and standardisation matter: ethanolic and CO2-extracted products perform less consistently. Pair with PSA monitoring; saw palmetto modestly lowers PSA without affecting cancer risk, which can mask rising PSA from a developing cancer.

Tier 2 evidence · Cochrane-supported on IPSS

Beta-sitosterol

60–130 mg/day in divided doses

The Wilt 1999 Cochrane review (4 RCTs, n=519) showed beta-sitosterol significantly improved IPSS and peak urinary flow vs placebo. Newer trials have not added much, but the original signal has held up. Mechanism: 5-alpha reductase modulation and anti-inflammatory effects. Often combined with saw palmetto in commercial products. Can be used as alternative to saw palmetto in users who didn't respond.

Tier 2 evidence · Older, mostly European data

Pygeum africanum (African plum)

100–200 mg/day standardised extract

Wilt 2002 Cochrane review (18 RCTs) supported pygeum at 100–200 mg/day for IPSS, nocturia, and urinary flow. Trials are mostly European, older, and not always well-controlled. Conservation concerns about African plum bark harvesting have driven supply variability. Reasonable second-line botanical option, particularly in users with prominent nocturia.

Tier 2 evidence · Often combined with pygeum

Stinging nettle root (Urtica dioica)

300–600 mg root extract/day

Several small RCTs (Safarinejad 2005, Lopatkin 2005) show modest IPSS improvements with nettle root extract, often combined with pygeum or saw palmetto. Mechanism: aromatase inhibition, SHBG-binding modulation. As monotherapy the data are thin; in combination products the evidence is more substantial.

Tier 3 evidence · Adjunct only

Zinc + selenium + lycopene

Zinc 15–30 mg, selenium 100–200 mcg, lycopene 15–30 mg daily

The Morgia 2010 trial combining serenoa + selenium + lycopene showed additive IPSS improvement. Lycopene from cooked tomato (and supplemented) has small prostate-related epidemiology. Zinc concentration in prostate tissue declines with BPH, though restoration via supplementation has not been shown to move clinical endpoints alone.

The lifestyle and behavioural base — usually higher yield than supplements

Bladder retraining and timed voiding — for urgency-predominant symptoms; works as well as some medications in mild LUTS.
Reduce evening fluid intake — stop fluids 2–3 hours before bed to reduce nocturia.
Limit caffeine and alcohol — both irritate the bladder and worsen frequency/urgency.
Double voiding — second attempt 1–2 minutes after the first improves emptying.
Pelvic floor physiotherapy — appropriate for select patients with pelvic floor dyssynergia or chronic pelvic pain overlap.
Weight loss — abdominal obesity associates with worse LUTS; modest weight loss improves symptoms in observational data.
Medication review — antihistamines, decongestants, anticholinergics, opioids, and diuretics all worsen LUTS; review with prescribers.
Resistance and aerobic exercise — independently associated with lower IPSS scores in cohort studies.

What to skip

Saw palmetto products that don't specify hexane extraction or standardisation — most negative trials used poorly-standardised products; specify Permixon-type extracts.
"Prostate health" 20-ingredient capsules — diluted ingredients at sub-trial doses; you cannot fit 320 mg saw palmetto + 130 mg beta-sitosterol + 200 mg pygeum in a single small capsule.
DHEA, pregnenolone, "T-boosters" — no BPH benefit; some may worsen symptoms by raising DHT in prostate tissue.
Bee pollen / Cernilton without standardisation — the Cochrane review found mixed results; the trial-grade product is hard to source over-the-counter.
Lycopene as monotherapy — modest in combinations; no IPSS-moving signal alone at supplement doses.
Magnesium / boron / calcium-D-glucarate for "prostate detox" — no clinical evidence in BPH.
"Adrenal" or "hormone reset" stacks — wrong target; BPH is driven by intraprostatic DHT and stromal-epithelial signalling, not adrenal hormones.

What to track

The International Prostate Symptom Score (IPSS, 7 questions plus quality-of-life item; 0–35 range) is the standard. Mild = 0–7, moderate = 8–19, severe = 20–35. Aim for a ≥3-point IPSS reduction at 12 weeks as a meaningful clinical response. Pair with subjective stream, hesitancy, and nocturia frequency. Get baseline and 12-month PSA; saw palmetto modestly lowers PSA without affecting cancer biology, so the trajectory rather than the absolute value is what matters. Post-void residual via bladder ultrasound is the safety endpoint — >100 mL persistent residual warrants urology referral.

Practical quick-start. Get a baseline DRE, PSA, IPSS, and ideally post-void residual. For mild symptoms (IPSS 8–14) with no red flags: hexane-extracted saw palmetto 320 mg/day + beta-sitosterol 130 mg/day for 12 weeks, alongside lifestyle base (evening fluid restriction, caffeine reduction, weight management). Reassess IPSS at 12 weeks. If moderate-to-severe (IPSS ≥15), or if no response by 12 weeks, see urology — alpha blockers (tamsulosin, alfuzosin) and 5-ARIs (finasteride, dutasteride) have larger effect sizes and are the appropriate next step.

Sources

Vela-Navarrete R, et al. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: systematic review and meta-analysis. BJU Int. 2018;122(6):1049–1065. PMID: 29694707
Barry MJ, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial (CAMUS). JAMA. 2011;306(12):1344–1351. PMID: 21954478
Wilt T, et al. Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2000;(2):CD001043. PMID: 10796745
Wilt T, et al. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;(1):CD001044. PMID: 11869585
Morgia G, et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter-controlled study. Urol Int. 2010;84(4):400–406. PMID: 20484965
Safarinejad MR. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herb Pharmacother. 2005;5(4):1–11. PMID: 16635963